Illustrative image – not actual.Private equity fund Advent International will acquire a controlling stake in pharmaceutical company ZCL Chemicals for an enterprise value of Rs 1,700 crore.
ZCL manufactures specialty active pharmaceutical ingredients (APIs) and advanced intermediates, with a focus on niche therapeutic areas and has a US Food and Drug Administration (US FDA)-approved facility.
Advent International has signed a definitive agreement to acquire a controlling stake in ZCL Chemicals.
This is Advent's third pharmaceuticals investment in India and the second in the API space.
In the past 12 months, Advent International has committed over USD 1.2 billion globally across the healthcare sector and USD 600 million in four Indian companies into healthcare, consumer and financial services.
ZCL manufactures specialty active pharmaceutical ingredients (APIs) and advanced intermediates, with a focus on niche therapeutic areas and has a US Food and Drug Administration (US FDA)-approved facility.
Advent International has signed a definitive agreement to acquire a controlling stake in ZCL Chemicals.
This is Advent's third pharmaceuticals investment in India and the second in the API space.
In the past 12 months, Advent International has committed over USD 1.2 billion globally across the healthcare sector and USD 600 million in four Indian companies into healthcare, consumer and financial services.
